BR112018067379A2 - conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição. - Google Patents
conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.Info
- Publication number
- BR112018067379A2 BR112018067379A2 BR112018067379A BR112018067379A BR112018067379A2 BR 112018067379 A2 BR112018067379 A2 BR 112018067379A2 BR 112018067379 A BR112018067379 A BR 112018067379A BR 112018067379 A BR112018067379 A BR 112018067379A BR 112018067379 A2 BR112018067379 A2 BR 112018067379A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- composition
- drug
- conjugate
- drug conjugate
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 6
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 abstract 1
- 229960003649 eribulin Drugs 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
toxinas ligantes e conjugados anticorpo-droga que se ligam a alvos de antígeno oncológico humano, tais como receptor alfa de folato e/ou proporcionam atividade de droga antitubulina são divulgados. as toxinas ligantes e conjugados anticorpo-droga compreendem uma fração de droga eribulina e podem ser internalizados em células que expressam antígeno alvo. a divulgação ainda se refere a métodos e composições para uso no tratamento do câncer por administração dos conjugados anticorpo-droga aqui proporcionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662302562P | 2016-03-02 | 2016-03-02 | |
PCT/US2017/020529 WO2017151979A1 (en) | 2016-03-02 | 2017-03-02 | Eribulin-based antibody-drug conjugates and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018067379A2 true BR112018067379A2 (pt) | 2019-01-15 |
Family
ID=58347964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018067379A BR112018067379A2 (pt) | 2016-03-02 | 2017-03-02 | conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição. |
Country Status (34)
Country | Link |
---|---|
US (4) | US10548986B2 (pt) |
EP (2) | EP3423105B1 (pt) |
JP (5) | JP6599019B2 (pt) |
KR (4) | KR20240007722A (pt) |
CN (4) | CN114191563A (pt) |
AR (3) | AR107787A1 (pt) |
AU (2) | AU2017225982B2 (pt) |
BR (1) | BR112018067379A2 (pt) |
CA (1) | CA3013791A1 (pt) |
CL (3) | CL2018002456A1 (pt) |
CO (1) | CO2018008667A2 (pt) |
CY (1) | CY1124628T1 (pt) |
DK (1) | DK3423105T3 (pt) |
ES (1) | ES2880402T3 (pt) |
HR (1) | HRP20211125T1 (pt) |
HU (1) | HUE054726T2 (pt) |
IL (2) | IL292946A (pt) |
JO (3) | JOP20170053B1 (pt) |
LT (1) | LT3423105T (pt) |
MA (1) | MA45280B1 (pt) |
MD (1) | MD3423105T2 (pt) |
MX (4) | MX2018010562A (pt) |
MY (1) | MY189113A (pt) |
PE (3) | PE20231050A1 (pt) |
PH (1) | PH12018501847A1 (pt) |
PL (1) | PL3423105T3 (pt) |
PT (1) | PT3423105T (pt) |
RS (1) | RS62108B1 (pt) |
RU (2) | RU2754369C2 (pt) |
SG (2) | SG10202007520WA (pt) |
SI (1) | SI3423105T1 (pt) |
TW (2) | TWI825834B (pt) |
UA (1) | UA125024C2 (pt) |
WO (1) | WO2017151979A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2607444C (en) * | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EA039366B1 (ru) | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
CA2990565A1 (en) | 2015-06-24 | 2016-12-29 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein containing bdnf and anti-human transferrin receptor antibody |
IL276191B2 (en) | 2016-12-26 | 2024-02-01 | Japan Chem Res | A new anti-human transferrin receptor antibody capable of penetrating the blood-brain barrier |
KR102634732B1 (ko) | 2017-04-05 | 2024-02-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 마크로시클릭 화합물 및 그의 용도 |
BR112020000141A2 (pt) | 2017-07-06 | 2020-07-14 | President And Fellows Of Harvard College | síntese de halicondrinas |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
EP3706803A4 (en) * | 2017-11-08 | 2021-08-04 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | CONJUGATES OF BIOMOLECULES AND THEIR USES |
US11407762B2 (en) | 2017-11-15 | 2022-08-09 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
IL305431A (en) | 2018-06-01 | 2023-10-01 | Eisai R&D Man Co Ltd | Antibody drug conjugates of splicing modulators and methods of use |
EP3801523A2 (en) | 2018-06-01 | 2021-04-14 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
KR20210042120A (ko) | 2018-08-06 | 2021-04-16 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 튜불린 저해제의 조합 |
BR112021011900A2 (pt) * | 2018-12-21 | 2021-09-08 | Novartis Ag | Anticorpos para pmel17 e conjugados dos mesmos |
CN110568121A (zh) * | 2019-07-11 | 2019-12-13 | 山东省药学科学院 | 一种艾日布林及含艾日布林的制剂中有关物质的检测方法 |
US11572414B2 (en) * | 2019-11-07 | 2023-02-07 | Eisai R&D Management Co., Ltd. | Eribulin antibody-drug conjugates and methods of use |
US20230074385A1 (en) | 2019-12-23 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Method for producing eribulin-based antibody-drug conjugate |
JP2023511163A (ja) | 2020-01-22 | 2023-03-16 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
KR20220018954A (ko) * | 2020-08-07 | 2022-02-15 | 주식회사 피노바이오 | 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도 |
CA3192058A1 (en) * | 2020-09-11 | 2022-03-17 | David George Potter | Anti-ceruloplasmin antibodies and uses thereof |
CN116390733A (zh) * | 2020-09-28 | 2023-07-04 | 纳夫罗根公司 | 用于治疗癌症的替代性格式化的抗间皮素抗体的组合物和用途 |
US20240024502A1 (en) * | 2020-10-18 | 2024-01-25 | Ardeagen Corporation | Anti-msln binding agents, conjugates thereof and methods of using the same |
CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
TW202304524A (zh) * | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1結合劑、其結合物及使用方法 |
EP4349371A1 (en) * | 2021-06-02 | 2024-04-10 | Bio-Thera Solutions, Ltd. | Drug conjugate and use thereof |
TW202310878A (zh) * | 2021-07-22 | 2023-03-16 | 大陸商上海森輝醫藥有限公司 | 艾日布林衍生物的藥物偶聯物 |
WO2023016488A1 (zh) * | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
TW202327661A (zh) * | 2021-09-16 | 2023-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 抗her3抗體藥物偶聯物及其組合物和用途 |
WO2023055376A1 (en) * | 2021-09-30 | 2023-04-06 | Virtuoso Binco, Inc. | Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof |
TW202317088A (zh) * | 2021-10-14 | 2023-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 艾日布林衍生物的製備方法 |
WO2023098691A1 (zh) * | 2021-12-01 | 2023-06-08 | 上海生物制品研究所有限责任公司 | 抗体药物偶联物及其用途 |
WO2023103854A1 (zh) * | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
WO2023124963A1 (zh) * | 2021-12-27 | 2023-07-06 | 昆山新蕴达生物科技有限公司 | 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用 |
WO2023143319A1 (zh) * | 2022-01-28 | 2023-08-03 | 启德医药科技(苏州)有限公司 | 抗体药物偶联物、药物组合物及用途 |
WO2023143320A1 (zh) * | 2022-01-28 | 2023-08-03 | 博瑞生物医药(苏州)股份有限公司 | 用于制备抗体药物偶联物的连接子、化合物及用途 |
WO2023155808A1 (zh) * | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
WO2023170247A1 (en) | 2022-03-11 | 2023-09-14 | Mablink Bioscience | Antibody-drug conjugates and their uses |
WO2023198079A1 (zh) * | 2022-04-12 | 2023-10-19 | 百奥泰生物制药股份有限公司 | 治疗her2阳性实体瘤的方法 |
WO2023200814A1 (en) | 2022-04-12 | 2023-10-19 | Eisai R & D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
WO2024078612A1 (en) * | 2022-10-14 | 2024-04-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linker-payload compound, conjugates and applications thereof |
Family Cites Families (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
PT954282E (pt) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | Preparacao de particulas para inalacao |
CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
US6019963A (en) | 1998-11-20 | 2000-02-01 | D.S.C. Products, Inc. | Deodorizing composition containing tea tree and eucalyptus oils |
US7109019B2 (en) | 1999-01-06 | 2006-09-19 | The Regents Of The University Of California | Gene cluster for production of the enediyne antitumor antibiotic C-1027 |
MXPA03010035A (es) | 2001-05-02 | 2004-06-30 | Purdue Research Foundation | Tratamiento y diagnostico de enfermedades mediadas por macrofagos. |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
EP1531846A4 (en) | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES |
EP1545613B9 (en) * | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
JP2004119755A (ja) | 2002-09-27 | 2004-04-15 | Alps Electric Co Ltd | 磁気検出素子及びその製造方法 |
US20040071540A1 (en) | 2002-10-15 | 2004-04-15 | Lucas Philip J. | Disposable/recyclable pallet system and method |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
BRPI0414568A (pt) | 2003-09-18 | 2006-11-07 | Combinatorx Inc | combinações de drogas para o tratamento de neoplasmas |
US6997024B2 (en) | 2003-10-01 | 2006-02-14 | Truth Hardware Corporation | Pull door lock |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
US20050148535A1 (en) | 2003-10-30 | 2005-07-07 | Lacasse Eric | IAP nucleobase oligomers and oligomeric complexes and uses thereof |
AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
US7117807B2 (en) | 2004-02-17 | 2006-10-10 | University Of Florida Research Foundation, Inc. | Dynamically modifiable polymer coatings and devices |
WO2006073419A2 (en) | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
JP2007537164A (ja) | 2004-05-07 | 2007-12-20 | マサチューセッツ・インスティテュート・オブ・テクノロジー | リン酸化bach1のbrca1brctドメイン認識と関係する癌治療のための方法および組成物 |
EP2522663B1 (en) | 2004-06-03 | 2015-04-01 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of halichondrin B |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008522624A (ja) | 2004-12-09 | 2008-07-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘミアスタリン(hemiasterlin)アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング |
WO2006076100A2 (en) | 2004-12-09 | 2006-07-20 | Eisai Co. Ltd. | Tubulin isotype screening in cancer therapy using halichondrin b analogs |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
GB0515025D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
KR20130113543A (ko) | 2005-08-19 | 2013-10-15 | 엔도사이트, 인코포레이티드 | 복수-약제 리간드 공액체 |
CA2620362A1 (en) | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A. | Comb polymers |
CA2632903C (en) | 2005-12-02 | 2015-11-24 | Vianova Labs, Inc. | Treatment of cancer and other diseases |
EP2021502A4 (en) | 2006-05-09 | 2010-08-25 | Mas Metabolic Analytical Servi | GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY |
US20150030534A1 (en) | 2013-07-26 | 2015-01-29 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
US20140037539A1 (en) | 2012-07-27 | 2014-02-06 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2481427A1 (en) | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
EP1977765A1 (en) | 2007-04-03 | 2008-10-08 | Diatos | Peptide prodrugs |
US8093410B2 (en) | 2007-10-03 | 2012-01-10 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
JP5065228B2 (ja) | 2007-10-30 | 2012-10-31 | 富士通株式会社 | 携帯端末装置 |
NO2842575T3 (pt) | 2008-03-18 | 2018-02-24 | ||
WO2009121031A1 (en) | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
SG189817A1 (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
RU2011104348A (ru) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
JP2010090117A (ja) | 2008-09-12 | 2010-04-22 | Santen Pharmaceut Co Ltd | スルホン酸エステル構造を導入したフェニル基を置換基として有する新規1,2,3,4−テトラヒドロキノキサリン誘導体からなるグルココルチコイド受容体アゴニスト |
BRPI0922807A2 (pt) | 2008-12-04 | 2015-12-22 | Abbott Lab | imonuglobulinas de domínio variável duplo e usos dos mesmos |
EP2810652A3 (en) | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
US20140339088A1 (en) | 2009-03-09 | 2014-11-20 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis methods for determining a property of a plurality of cancer cells |
RU2011148913A (ru) | 2009-05-01 | 2013-06-10 | Эбботт Лэборетриз | Иммуноглобулин с двумя вариабельными доменами и его применение |
US8686520B2 (en) * | 2009-05-29 | 2014-04-01 | International Business Machines Corporation | Spin-torque magnetoresistive structures |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
WO2011022264A1 (en) * | 2009-08-15 | 2011-02-24 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CN102803254B (zh) | 2010-01-26 | 2016-09-14 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物 |
CA2794266C (en) | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
SI2571532T1 (sl) | 2010-05-14 | 2017-10-30 | Abbvie Inc. | Proteini, ki vežejo IL-1 |
JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9089570B2 (en) | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
US9192677B2 (en) | 2010-09-07 | 2015-11-24 | Johannes Kepler Universität Linz | Biodegradable, water soluble and pH responsive poly(organo)phosphazenes |
WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
WO2012075361A2 (en) | 2010-12-02 | 2012-06-07 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
KR20130133247A (ko) | 2010-12-21 | 2013-12-06 | 애브비 인코포레이티드 | Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
UY33827A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
EP2675474B1 (en) | 2011-02-15 | 2019-01-16 | Vaxiion Therapeutics, LLC | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
EP2680839A1 (en) | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
WO2012118978A1 (en) | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
WO2012121973A1 (en) | 2011-03-04 | 2012-09-13 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
JP5971769B2 (ja) | 2011-03-15 | 2016-08-17 | ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | アントラサイクリン療法を用いて乳癌を処置する方法 |
EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
EP2670866A4 (en) | 2011-04-05 | 2015-09-02 | Translational Genomics Res Inst | BIOMARKERS AND METHODS OF USE |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
MX359217B (es) | 2011-05-27 | 2018-09-19 | Ambrx Inc | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales. |
WO2012170640A1 (en) | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
ES2622578T3 (es) | 2011-06-10 | 2017-07-06 | Mersana Therapeutics, Inc. | Conjugados de proteína-polímero-fármaco |
EP3321281B1 (en) | 2011-08-05 | 2019-11-27 | biOasis Technologies Inc | P97 fragments with transfer activity |
WO2013078559A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
CN104024237B (zh) | 2011-12-16 | 2016-02-24 | 阿方拉研究股份有限公司 | 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体 |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
WO2013092983A2 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
CA2860446C (en) | 2011-12-29 | 2017-01-10 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
WO2013130093A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
EP2830648A4 (en) | 2012-03-29 | 2015-12-02 | Altor Bioscience Corp | METHODS OF TREATING NEOPLASIA |
EP2831082B1 (en) | 2012-03-30 | 2019-02-20 | Sandoz AG | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein |
CN104684579A (zh) | 2012-04-02 | 2015-06-03 | 梅里麦克制药股份有限公司 | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 |
US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
BR112014028396A2 (pt) | 2012-05-15 | 2018-05-29 | Diatech Oncology | processo de isolamento/purificação de célula de tumor e métodos para uso da mesma |
SG11201408153YA (en) | 2012-06-07 | 2015-01-29 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
MX2014014831A (es) | 2012-06-08 | 2015-02-12 | Hoffmann La Roche | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. |
AU2013277169B2 (en) | 2012-06-19 | 2017-02-02 | Ambrx, Inc. | Anti-CD70 antibody drug conjugates |
CA2877378A1 (en) | 2012-06-29 | 2014-01-03 | Nanostring Technologies, Inc. | Methods of treating breast cancer with gemcitabine therapy |
US9220695B2 (en) | 2012-06-29 | 2015-12-29 | The Research Foundation For The State University Of New York | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances |
CA2878733C (en) | 2012-07-12 | 2021-09-14 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
US9872919B2 (en) | 2012-09-19 | 2018-01-23 | The Research Foundation For The State University Of New York | Prodrugs for selective anticancer therapy |
AU2013326463B2 (en) | 2012-10-04 | 2018-01-18 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
US20150275306A1 (en) | 2012-10-10 | 2015-10-01 | Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis | Methods and means for predicting resistance to anti-cancer treatment |
WO2014063443A1 (zh) | 2012-10-22 | 2014-05-01 | Zhang Yuliang | 自冷式热力做功方法 |
JP6855661B2 (ja) | 2012-10-23 | 2021-04-07 | シンアフィックス ビー.ブイ. | 修飾抗体、抗体コンジュゲート及びそれらを調製する方法 |
PT2917195T (pt) | 2012-11-05 | 2018-02-09 | Pfizer | Análogos de spliceostatina |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
CN105283182A (zh) | 2012-12-03 | 2016-01-27 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶的杂环抑制剂治疗癌症 |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
JP6334553B2 (ja) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス,インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
WO2014096551A1 (en) | 2012-12-21 | 2014-06-26 | Glykos Finland Oy | Linker-payload molecule conjugates |
US20150182634A1 (en) | 2012-12-28 | 2015-07-02 | Cody P. Coyne | Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action |
EP2964245A4 (en) | 2013-01-19 | 2016-09-21 | Univ New York | PEPTIDES AND PEPTIDOMIMETIC HYDROGEN-LINKED SUBSTITUTE FOR REACTIVATION OF P53 |
WO2014113794A2 (en) | 2013-01-19 | 2014-07-24 | New York University | Oligooxopiperazines for p53 reactivation |
US20140220112A1 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
EP2950784B1 (en) | 2013-02-01 | 2021-04-07 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into liposomes |
US9849193B2 (en) | 2013-02-08 | 2017-12-26 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
US9333211B2 (en) | 2013-02-22 | 2016-05-10 | University Of Houston System | Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
WO2015073072A1 (en) | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
NZ711948A (en) | 2013-03-13 | 2020-02-28 | Oncoceutics Inc | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
US20160022829A1 (en) | 2013-03-14 | 2016-01-28 | Mersana Therapeutics, Inc. | Tubulysin compounds and conjugates thereof |
CN105377252A (zh) | 2013-03-14 | 2016-03-02 | 佛罗里达大学研究基金会 | 利用天然化合物和/或饮食调控癌症 |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
MY174813A (en) | 2013-03-15 | 2020-05-16 | Zymeworks Inc | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
US10233219B2 (en) | 2013-04-12 | 2019-03-19 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
WO2014176284A1 (en) | 2013-04-22 | 2014-10-30 | Avelas Biosciences, Inc. | Selective drug delivery compositions and methods of use |
GB2513405A (en) | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
ES2759503T3 (es) | 2013-05-02 | 2020-05-11 | Glykos Finland Oy | Conjugados de una glicoproteína o un glicano con una carga útil tóxica |
AR096238A1 (es) | 2013-05-15 | 2015-12-16 | Alphora Res Inc | Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | ポリペプチドの酵素的結合 |
WO2014206466A1 (en) | 2013-06-26 | 2014-12-31 | Afg Technologies S.À.R.L | Screening, diagnosis, prognostication and treatment of ovarian cancer |
AU2014286880B2 (en) | 2013-07-03 | 2017-12-14 | Sandoz Ag | Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups |
WO2015017729A1 (en) | 2013-07-31 | 2015-02-05 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis methods for determining a property of a plurality of cancer cells |
US20160166637A1 (en) | 2013-08-02 | 2016-06-16 | Virginia Tech Intellectual Properties, Inc. | Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
JP2016537010A (ja) | 2013-09-09 | 2016-12-01 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット |
WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
US20150093331A1 (en) | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
US9878049B2 (en) | 2013-10-09 | 2018-01-30 | The University Of Akron | High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy |
AU2014331714B2 (en) | 2013-10-11 | 2019-05-02 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
MX2016003744A (es) | 2013-10-11 | 2016-08-11 | Us Health | Anticuerpos tem8 y su uso. |
US9617521B2 (en) | 2013-10-21 | 2017-04-11 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
CN114716453A (zh) | 2013-11-04 | 2022-07-08 | 卫材R&D管理有限公司 | 软海绵素b的类似物合成中有用的大环化反应和中间体 |
WO2015069266A1 (en) | 2013-11-07 | 2015-05-14 | Flynn Daniel L | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
CN106163524B (zh) | 2013-11-15 | 2019-11-08 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法 |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
EP3077399B1 (en) | 2013-12-06 | 2019-02-20 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin b analogs |
WO2015095784A1 (en) | 2013-12-19 | 2015-06-25 | Luminus Biosciences, Inc. | Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration |
US20160375234A1 (en) | 2014-01-10 | 2016-12-29 | Atossa Genetic Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN104784699B (zh) | 2014-01-20 | 2019-05-03 | 博瑞生物医药(苏州)股份有限公司 | 叶酸受体结合配体-药物偶联物 |
JP5957637B2 (ja) * | 2014-02-03 | 2016-07-27 | 国立研究開発法人国立がん研究センター | 抗TissueFactorモノクローナル抗体 |
WO2015114171A1 (en) | 2014-02-03 | 2015-08-06 | Eidgenoessische Technische Hochschule Zurich | Small molecule drug conjugates |
EP2913064A1 (en) | 2014-02-26 | 2015-09-02 | celares GmbH | Branched drug-linker conjugates for the coupling to biological targeting molecules |
TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Alphora研發股份有限公司 | (s)-1-((2r,3r,4s,5s)-5-烯丙-3-甲氧-4-(對甲苯磺醯甲基)四氫呋喃-2-基)-3-氨基丙-2-醇之結晶衍生物 |
CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
US9260478B2 (en) * | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
EP3967303A1 (en) | 2014-04-08 | 2022-03-16 | The Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
WO2015160833A1 (en) | 2014-04-14 | 2015-10-22 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
WO2015161247A1 (en) * | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
WO2015195925A1 (en) * | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
EP3069734A1 (en) * | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
WO2015151079A2 (en) | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
-
2017
- 2017-03-02 LT LTEP17711475.8T patent/LT3423105T/lt unknown
- 2017-03-02 PT PT177114758T patent/PT3423105T/pt unknown
- 2017-03-02 CA CA3013791A patent/CA3013791A1/en active Pending
- 2017-03-02 MD MDE20190061T patent/MD3423105T2/ro unknown
- 2017-03-02 CN CN202111360093.5A patent/CN114191563A/zh active Pending
- 2017-03-02 HU HUE17711475A patent/HUE054726T2/hu unknown
- 2017-03-02 RS RS20210889A patent/RS62108B1/sr unknown
- 2017-03-02 KR KR1020247000482A patent/KR20240007722A/ko not_active Application Discontinuation
- 2017-03-02 TW TW111125421A patent/TWI825834B/zh active
- 2017-03-02 WO PCT/US2017/020529 patent/WO2017151979A1/en active Application Filing
- 2017-03-02 AU AU2017225982A patent/AU2017225982B2/en active Active
- 2017-03-02 SI SI201730837T patent/SI3423105T1/sl unknown
- 2017-03-02 PE PE2023001172A patent/PE20231050A1/es unknown
- 2017-03-02 CN CN202111360563.8A patent/CN114272389B/zh active Active
- 2017-03-02 CN CN201780022381.5A patent/CN108883198B/zh active Active
- 2017-03-02 PL PL17711475T patent/PL3423105T3/pl unknown
- 2017-03-02 IL IL292946A patent/IL292946A/en unknown
- 2017-03-02 KR KR1020187028407A patent/KR102445255B1/ko active IP Right Grant
- 2017-03-02 KR KR1020227022691A patent/KR20220101204A/ko not_active Application Discontinuation
- 2017-03-02 PE PE2018001578A patent/PE20181953A1/es unknown
- 2017-03-02 JO JOP/2017/0053A patent/JOP20170053B1/ar active
- 2017-03-02 UA UAA201809739A patent/UA125024C2/uk unknown
- 2017-03-02 DK DK17711475.8T patent/DK3423105T3/da active
- 2017-03-02 PE PE2023001171A patent/PE20231049A1/es unknown
- 2017-03-02 CN CN202111360555.3A patent/CN114191428A/zh active Pending
- 2017-03-02 RU RU2018134331A patent/RU2754369C2/ru active
- 2017-03-02 MY MYPI2018001424A patent/MY189113A/en unknown
- 2017-03-02 RU RU2021125492A patent/RU2021125492A/ru unknown
- 2017-03-02 KR KR1020227022690A patent/KR102456433B1/ko active IP Right Grant
- 2017-03-02 JP JP2018545210A patent/JP6599019B2/ja active Active
- 2017-03-02 AR ARP170100524A patent/AR107787A1/es unknown
- 2017-03-02 US US15/448,497 patent/US10548986B2/en active Active
- 2017-03-02 MX MX2018010562A patent/MX2018010562A/es unknown
- 2017-03-02 SG SG10202007520WA patent/SG10202007520WA/en unknown
- 2017-03-02 EP EP17711475.8A patent/EP3423105B1/en active Active
- 2017-03-02 MA MA45280A patent/MA45280B1/fr unknown
- 2017-03-02 BR BR112018067379A patent/BR112018067379A2/pt active Search and Examination
- 2017-03-02 TW TW106106901A patent/TWI772288B/zh active
- 2017-03-02 ES ES17711475T patent/ES2880402T3/es active Active
- 2017-03-02 SG SG11201806515RA patent/SG11201806515RA/en unknown
- 2017-03-02 EP EP20204172.9A patent/EP3824909A1/en active Pending
-
2018
- 2018-02-09 US US15/892,921 patent/US10322192B2/en active Active
- 2018-08-16 CO CONC2018/0008667A patent/CO2018008667A2/es unknown
- 2018-08-28 IL IL261428A patent/IL261428A/en unknown
- 2018-08-28 CL CL2018002456A patent/CL2018002456A1/es unknown
- 2018-08-30 PH PH12018501847A patent/PH12018501847A1/en unknown
- 2018-08-31 MX MX2023003806A patent/MX2023003806A/es unknown
- 2018-08-31 MX MX2023003808A patent/MX2023003808A/es unknown
- 2018-08-31 MX MX2023003809A patent/MX2023003809A/es unknown
-
2019
- 2019-10-01 JP JP2019181469A patent/JP6870051B2/ja active Active
- 2019-12-04 US US16/702,720 patent/US20200297860A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084451A patent/JP2020128413A/ja active Pending
-
2021
- 2021-01-07 CL CL2021000049A patent/CL2021000049A1/es unknown
- 2021-01-07 CL CL2021000048A patent/CL2021000048A1/es unknown
- 2021-02-10 AR ARP210100339A patent/AR121302A2/es unknown
- 2021-02-10 AR ARP210100338A patent/AR121301A2/es unknown
- 2021-04-13 JO JOP/2021/0073A patent/JOP20210073A1/ar unknown
- 2021-04-13 JO JOP/2021/0074A patent/JOP20210074A1/ar unknown
- 2021-07-14 HR HRP20211125TT patent/HRP20211125T1/hr unknown
- 2021-08-02 CY CY20211100686T patent/CY1124628T1/el unknown
- 2021-08-25 JP JP2021137504A patent/JP7254861B2/ja active Active
-
2022
- 2022-12-07 US US18/062,996 patent/US20230398228A1/en active Pending
-
2023
- 2023-03-29 JP JP2023053129A patent/JP2023082096A/ja active Pending
- 2023-12-20 AU AU2023285804A patent/AU2023285804A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018067379A2 (pt) | conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição. | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
BR112019022972A2 (pt) | Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
BR112018070580A2 (pt) | métodos e composições para terapia com células t car | |
BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
BR112014031394A8 (pt) | Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral | |
BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
BR112014026088A2 (pt) | produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos | |
BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
BR112016016880A2 (pt) | Combinação para tratar câncer e seu uso, kit, e composição farmacêutica | |
EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
BR112022005026A2 (pt) | Conjugados terapêuticos | |
BR112016013026A2 (pt) | compostos para receptor-3 de fator de crescimento de fibroblasto (fgfr3) e métodos de tratamento | |
UY35250A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos. | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
BR112018067923A2 (pt) | métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3 | |
EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
BR112014016723A2 (pt) | método para o tratamento de câncer de mama | |
MX2021013391A (es) | Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo. | |
BR112018005494A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença. | |
BR112018015448A2 (pt) | conjugado anticorpo-fármaco, composição farmacêutica, métodos para liberar um agente ativo, para tratar uma doença, para inibir progressão de tumor e para inibir, diminuir ou eliminar a capacidade metastática de um tumor, e, kit. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |